No waste, no pressure
and Carriuolo J
DPP-4 Inhibitors: review of vildagliptin phase 3 data
Key results (Phase 3): In a 68-week Phase 3a trial published in The New England Journal of Medicine , cagrilintidesemaglutide (CagriSema) produced large mean weight loss (reported as ~22.7% at 68 weeks in the main efficacy analysis)
The good news is that glutathiones melanin-inhibiting action can, in theory, help reduce hyperpigmentation regardless of the cause
(2008) reported that ingestion of a range of doses between 215 g of citrulline had no adverse effect on hematological markers (leucocytes, polymorphonuclears, lymphocytes, monocytes, erythrocytes, Hb) or biochemical markers (calcium, total proteins, albumin, C-reactive protein, urea, creatinine, glucose, cholesterol, triacylglycerol)